Graeme Holm

The Australian Financial Review recently recognized the Infinity Group Australia as one of the top 100 most innovative companies of the year. The company was originally founded by Graeme Holm back in 2013 along with his business partner, Rebecca Walker and, ever since its inception, it’s become one of the fastest-growing companies in the nation. It is also noted for its philanthropic endeavors as the company seeks to help countless people in Australia get themselves out of debt, improve their current financial situations and ensure their futures are financially secure. As it happens, this is now the seventh year that the company has made it on this list. This particular list names the most innovative companies throughout Australia and New Zealand and is the only one of its kind in the entire country.

This particular publication reaches around 1.8 million readers across the country. This year’s list was judged by Inventium, one of Australia’s leading consultaing firms, who compiled the list alongside a panel of experts on industry and business growth. Some of the categories they look at include how well they are able to address the problem they’re attempting to resolve, the quality of the solution and how well it works in the real world, innovation, culture, strategy and many others. IGA was selected from over 1,000 companies throughout the country and came in at number 58.

Their founder, Graeme Holm, graciously accepted this honor at the awards ceremony on July 30, 2018, where he expressed his gratitude to the Australian Financial Review for this award and noted how grateful he felt to be given this honor. Given their position on the list, they rank in the top 5.8% of all the companies selected for this particular honor. He also thanked his team for their constant dedication and hard work as well as his partner, Rebecca Walker. Holm has obtained over 15 years of financial experience in the financial industry and is dedicated to keeping banks and other financial institutions morally upright and honest. He also has a personal commitment to helping families who are struggling financially to keep their heads above water.

This passion and dedication are what eventually inspired him to create his own company which has since become a leader in the financial industry. The company is currently based out of Bella Vista, New South Wales which is located in Sydney. IGA is constantly expanding and finding more ways to help as many people as they can. Their commitment to philanthropy and the wellness of others is what has led to their success as they manage to eliminate about $41,000 of debt per year. So we congratulate them on this honor and wish them the best. Learn more : http://meetgraemeholm.com.au/

The Efforts of Dr. Scott Rocklage Towards a Muscular Dystrophy Remedy

Myotonic Dystrophy 1 or DM1 is a genetic disorder affecting RNAs in a person DNA. Expansion Therapeutics dealing with this case has been trying to raise funds and have already raised $55.3 million in 2018. Led by 5 AM Ventures Managing Partner Scott Rocklage, Ph. D., several other companies such as Novartis Venture Fund, Kleiner Perkins, Sanofi Ventures, Alexandria Venture Investments and RA Capital Management have been involved in raising funds. DM1 does not have effective treatment methods necessitating the need for such efforts.

 

When some RNAs molecules from the DNA are transformed into proteins and accumulate, they reach toxic levels resulting into DM1. This affects the hormonal system, the heart, the respiratory system, muscles, and central nervous system rendering them inefficient. DM1 affects entire families with each following generation becoming worse.

 

Expansion therapists have given priority to expansion repeat diseases, which are inherited disorders that do not respond positively to updated medical interventions. Scott Rocklage when issuing a press release announced Matthew D. Disney as the lead scientist of the team. Dr. Disney said they are on the verge of producing small molecule treatments targeting the RNAs. This will be a significant breakthrough for patients who currently have no options. Scott Rocklage, Dr. Disney, and Expansion Therapist shave devoted their research until they come up with a treatment that will give hope for DM1 patients.

 

Scott Rocklage is a widely experienced medical health management professional with over 30 years experience in the field. His medical treatments endeavors have led to FDA approval of Cubicin, Teslascan and Omniscan medications in addition to other submissions of other medicines for clinical trials. Scott is an inventor with over 30 patents some of them co-invented. Additionally, he had written over 100 publications that have been peer-reviewed.

 

Scott went to the University of California, Berkeley for his B.S in Chemistry and Massachusetts Institute of Technology (MIT) for his Ph. D. in Chemistry. He had a chance to work with 2005 Nobel Peace Prize winner in Chemistry Dr. Richard Schorck when studying at MIT. Scott Rocklage is a leader having been chairman, president, CEO of several companies such as NycomedSalutar, Cubist Pharmaceuticals, and Catalytica. He is the chairman of boards of Kinestral, Rennovia and Cidara.

 

Visit http://5amventures.com/team/scott-m-rocklage-phd/ to learn more.